All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

  TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub
Brought to you by Scientific Education Support

The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

EHA 2025 top abstracts: What's hot in AML?

By Sari Cumming

Share:

Jun 9, 2025

Learning objective: After reading this article, learners will be able to cite a new clinical development in acute myeloid leukemia.

To help navigate the exciting content being presented at the European Hematology Association 2025 Congress, the AML Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in AML.

EHA 2025: Top abstracts in AML

Thursday, June 12

S135All-oral decitabine-cedazuridine (DEC-C) + venetoclax (VEN) in patients with newly diagnosed acute myeloid leukemia (AML) ineligible for induction chemotherapy: Phase 1/2 clinical trial resultsGail Roboz
S136Ziftomenib combined with intensive induction chemotherapy (7+3) in newly diagnosed NPM1-m or KMT2A-r acute myeloid leukemia (AML): Updated phase 1A/B results from KOMET-007Harry Erba
S137RP2D determination of bleximenib in combination with VEN+AZA: Phase 1b study in ND & R/R AML with KMT2A/NPM1 alterationsAndrew Wei

Saturday, June 14

S149Phase 3 study of intensive chemotherapy with or without dasatinib in patients with core-binding factor acute myeloid leukemia - final analysis of the AMLSG 21-13 trialHartmut Döhner
S146Refinement of the ELN2022 prognostic subgroups in a real-life cohort of 1747 intensively treated adult AML patients of the PETHEMA registryJoaquín Martinez-Lopez
S267Allogenic hematopoietic stem cell transplantation in AML patients treated with azacitidine and venetoclax: a retrospective multicenter real-life study by French Auraml groupUrbain Tauveron-Jalenques
S268Impact of hypomethylating agents +/- venetoclax for the management of acute myeloid leukemia and myelodysplastic patients relapsing after allogeneic stem cell transplantation: A subanalysis on 308 patients of the GITMO AML/MDS-Relapse registry study.Michele Malagola

Sunday, June 15

LB4005HCT frailty scale (HCT-FS) for assessing frailty in allogeneic hematopoietic cell transplant patients. Results from a multicenter and prospective Canadian and Spanish initiativeMaria Queralt Salas
S140The combination of a FLT3-ITD, NPM1mut and an epigenetic regulatory gene mutation confers unique sensitivity to quizartinib: Analysis from the QuANTUM-First trialMark Levis
S142Phase I/II study of decitabine, venetoclax, and quizartinib triplet combination in FLT3-ITD mutated AMLMusa Yilmaz
S143Long-term follow-up of predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib versus salvage chemotherapy in the phase 3 commodore trialJaymini Patel
S144A CD33-deleted allograft (Trem-cel) enables gemtuzumab ozogamicin maintenance post-hematopoietic cell transplant with therapeutic exposures and low toxicity in patients with acute myeloid leukemiaGuenther Koehne

Posters

PF473Ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemia: Phase 1b/2 clinical activity and safety results from the pivotal KOMET-001 studyAmir Fathi
PF474Long-term real-world experience with CPX-351 treatment for acute myeloid leukemia in EnglandAlexandrina Lambova
PF480Final results of VEN A QUI trial: A phase I-II trial comparing venetoclax with low dose cytarabine or azacitidine combined with quizatinib in non-fit patients with acute myeloid leukemiaJuan Miguel Bergua Burgues
PF486Time to treatment initiation and clinical outcomes in non-intensively treated adult acute myeloid leukemia: A PETHEMA-GPLA-ACHO-GRELAM registry studyEduardo Rodríguez-Arbolí
PF516Effect of mutation type and co-mutations on response to olutasidenib in patients with relapsed/refractory mutated IDH1 AMLStéphane De Botton
PS1470Risk stratification of newly diagnosed acute myeloid leukemia treated with venetoclax in combination with intensive chemotherapyWei-Ying Jen 
PS1471A phase IB/2 trial of an all-oral “triplet” regimen for IDH-mutated myeloid malignancies: Decitabine/cedazuridine and venetoclax in combination with ivosidenib/enasidenibJennifer Marvin-Peek 
PS1480Phase II study of cladribine with low dose cytarabine and venetoclax alternating with azacytidine and venetoclax for newly diagnosed acute myeloid leukemiaAlex Bataller 
PS1482High efficiency of salvage therapy combining 7 days venetoclax and G-CSF, fludarabine, high-dose cytarabine, and mitoxantrone followed by allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloblastic leukemiaAhmad Ibrahim 
PS1483Primary results STIMULUS-AML1: A large, international, phase II study of sabatolimab combined with azacitidine and venetoclax as frontline therapy for unfit acute myeloid leukemia (AML) patients (pts)Amer M. Zeidan 
PS1496Outcomes of adult patients with newly diagnosed IDH-mutated acute myeloid leukemia receiving intensive chemotherapy plus venetoclaxJennifer Croden
PS1536Allogeneic transplantation vs. chemotherapy as consolidation strategies in older acute myeloid leukemia patients after first complete remission: A systematic review and meta-analysisCilomar Martins de Oliveira Filho 
PS1540Prognostic impact of the AML60+ score for patients with acute myeloid leukemia treated with hypomethylating agentsTobias Silzle  
PB2534Venetoclax-based regimens versus intensive chemotherapy as a bridge to allogeneic hematopoietic stem cell transplantation in patients with therapy-related acute myeloid leukemiaEkaterina Romaniuk 

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EHA 2025

Your opinion matters

What barriers do you encounter when conducting multiple MRD tests during treatment?

Newsletter

Subscribe to get the best content delivered to your inbox